Scientific Industries (SCND) Registration Filing summary

Company overview and business model

• Designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems for research use in universities, pharma, and other industries.

• Operates two segments: Benchtop Laboratory Equipment (mixers, shakers, scales, pill counters) and Bioprocessing Systems (smart sensors, analytics, software for bioprocessing).

• Bioprocessing segment is a strategic growth focus, with recent product launches and an acquisition to expand capabilities.

• Products are sold through distributors, online, and direct sales, with significant international operations, especially in Germany.

Financial performance and metrics

• Net loss of $1.78M for Q1 2025, $6.45M for 2024, and $9.09M for 2023; accumulated deficit of $35.7M as of March 31, 2025.

• Net revenues for 2024 were $10.7M, down 3.6% from 2023; gross profit margin decreased to 44.2% in 2024.

• Cash and equivalents were $587,900 at end of 2024, with negative cash flow from operations and a going concern warning.

• Benchtop segment is profitable, but bioprocessing expansion drives ongoing losses.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; company will receive proceeds only from warrant exercises, to be used for working capital.

• Ongoing need for additional capital to fund bioprocessing development and commercialization; no committed external funding sources.